Pharmaceuticals

Essentials tag unlikely to benefit pharmaceutical companies in Q1

Channel stocking in US in March quarter, lockdown impact hint at drop in earnings

Top govt scientists tell MPs Covid-19 vaccine at least a year away

Reliance of Indian pharma industry on Chinese APIs a 'huge strategic concern' with few short-term solutions, they say; meanwhile, CSIR says Covid offers a good opportunity to check brain drain

Cipla set to undercut rivals with low-priced generic remdesivir: Report

The drug will be available through the government and hospitals only, the company said

Despite poor show in Q4, India Inc's combined dividend payout rises 6.5%

Experts attribute the higher payout to the change in dividend law and cut in corporate income tax.

DRL to launch innovator brand of favipiravir, is silent on pricing

Ties up with Fujifilm for exclusive rights over Avigan for Indian market, can sell overseas too

Pharmaceuticals body seeks faster clearances of imported goods at ports

A senior official of the ministry of commerce said most of the goods that have to be cleared by the customs came from China

Gilead prices Covid-19 drug remdesivir at $2,340 in developed nations

Remdesivir is expected to be in high demand as one of the only treatments so far shown to alter the course of Covid-19

Infosys launches personalised medicine solution for pharmaceutical cos

The solution uses advanced analytics to manage individual patient treatment lifecycle from enrolment and scheduling to post medical treatments and can notably reduce patient treatment lifecycle

Sun Pharma to launch its first innovative product for psoriasis in Japan

Nod for Ilumya, a specialty product, would strengthen firm's dermatology portfolio in Japan, but analysts caution that the segment has been witnessing price erosion of late

The oil factor

The surplus should not be a cause for any celebration

Is India right in recommending HCQ despite the uncertainties around it?

HCQ was dropped from the solidarity trial that WHO was conducting as a part of a global effort in May.

Sanofi stops enrolling Covid-19 patients in hydroxychloroquine trials

The moves come after the World Health Organization paused its large trial of hydroxychloroquine, prompting several European governments to ban the use of the drug

Lupin reports 25% fall in pre-tax profit at Rs 412 cr in Q4 on low sales

On a sequential basis, however, the company fared better, both in terms of sales and profits. The stock ended day's trade at Rs 869.8, down 1.3 per cent.

Specialty products segment key to Sun Pharma's growth prospects

Pricing pressure in US, lockdown may dent near-term prospects

Pharma, chemical stocks lead under lockdown, Aurobindo is top performer

Within BSE-500, 79% stocks gave positive returns in two months of lockdown

'Talk to experts to make self-reliant slogan work'

For manufactured products, the stated policy since the 1950s was to allow imports of only the goods that were not being made in India in sufficient quantities

Covid-19: ICMR issues guidance on antibody test kits, lists manufacturers

ICMR in its guidance clearly stated that these rapid antibody tests are not recommended for diagnosis of Covid-19 infection

Covid-19: Lockdown exit plans highlight divergence in emerging markets

China, S Korea stocks outperform as restrictions are rolled back

Opportunity for Make in India

How India can make the most of the opportunity presented by the groundswell of emotion against China for its disinformation about coronavirus

Drug shortages in US market, compliance gains positive for pharma exporters

Shortage of drugs in the US market is at five-year highs